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Abstract
There has been a lot of focus on osteonecrosis of the jaws associated with the usage of bisphosphonates 
both in dental and medical literature in recent years. However, the exact pathogenesis of bisphosphonate-
related osteonecrosis of the jaws remains unclear. Against the background of emerging evidence of an 
evolving condition, it is not surprising that there is a lack of robust evidence-based recommendations 
on dental treatment of patients on bisphosphonates. This paper seeks to provide a rational approach 
to the dental management of patients on bisphosphonates based on current literature. [Singapore 
Dent J 2011;32(1):1–13]
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Introduction
Bisphosphonates are used to treat osteoporosis, 
multiple myeloma, metastatic neoplasms with 
skeletal involvement, Paget’s disease of bone, 
other metabolic bone diseases. Bisphosphonates 
come in intravenous (IV) and oral forms. IV bisphos-
phonates are used for multiple myeloma and 
metastatic neoplasms with skeletal involvement 
while the oral bisphosphonates are used mainly 
for osteoporosis. However, IV bisphosphonate 
(zoledronic acid) has recently been administered 
once yearly to treat osteoporosis.1 The pharmaco-
logic characteristics and the usual dosing of the 
bisphosphonates are described in Table 1.
Bisphosphonates are analogues of inorganic py-
rophosphates that have a high affinity for hydroxy-
apatite crystals.10,11 They are incorporated into 
the skeleton without being degraded and are re-
markably persistent drugs. Aminobisphosphonates 
which contain nitrogen side chain have much 
higher potency and longer half-life compared to 
nonaminobisphosphonates. The estimated half-
life for alendronate is up to 12 years.12 The potency 
of bisphosphonate is usually compared relative 
to etidronate which is the least potent non-
nitrogen containing bisphosphonate. Zoledronic 
acid is the most potent of the group and is 
10,000 more potent relative to etidronate. This 
is followed by pamidronate with relative potency 
of 1,000–5,000 and alendronate with relative 
potency of 1,000.
Mechanisms of Action of Bisphosphonate
Bisphosphonates are powerful inhibitors of os-
teoclast activity. They cause the induction of non-
hydrolyzable adenosine triphosphate analogue 
that induces cellular apoptosis and inhibition of 
farnesyl diphosphonate synthase which disrupts 
cholesterol synthesis resulting in dysregulation of 
intracellular transport, cytoskeletal organization 
and cell proliferation. This leads to inhibition of os-
teoclast function, reduce osteoclast recruitment, 
and induce osteoblastic production of osteoclast-
inhibiting factor.13–15
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Bisphosphonate Related Osteonecrosis 
of Jaws
The first report which described bisphosphonate 
related osteonecrosis of jaws (BRONJ) was in 2003 
by Marx.16 He observed painful exposed bone in 
mandible, maxilla or both jaws in 36 patients who 
were treated with intravenous bisphosphonates. 
Subsequently, more reports on bisphosphonate-
associated osteonecrosis of jaws were published 
(Table 2). Yeo et al17 reported five cases of bi-
sphosphonate-related osteonecrosis of the jaws 
in Singapore.
Pathogenesis of BRONJ
Despite the numerous publications, the patho-
genesis of BRONJ remains elusive. It is obvious 
that in BRONJ the problem occurs in the bone 
but studies have indicated that the soft tissue 
of the oral mucosa may also be involved. It has 
been proposed that bisphosphonates, which ac-
cumulate in the bone, have direct toxic effects 
on the oral epithelium and inhibit normal heal-
ing of soft tissue lesions caused by either dental 
extractions or some other trauma.64,65 The 
failure of soft tissue to heal would result in the 
exposure of the bone, which then becomes 
necrotic.
There are a number of hypotheses associated 
with the pathogenesis of BRONJ.
Suppression of bone remodelling
Nearly every report on BRONJ alludes to bisphos-
phonate-induced bone remodeling suppression 
as a likely mechanism. Osteoclasts are the main 
cellular target of bisphosphonates and osteoclast-
mediated bone remodeling is suppressed through 
disruption of intracellular pathways. It has been 
Table 1. Characteristics of bisphosphonates available
Drug
 Route of Nitrogen Relative 
Indication and usual dosage administration containing potency
Etidronate2 Oral No 1  Paget’s disease: 5–20 mg/kg/day
 × 3–6 mo
Tiludronate3 Oral No 50 Paget’s disease: 400 mg/day × 3 mo
Alendronate4 Oral Yes 1,000  Osteoporosis treatment: 
 70 mg once/wk
     Osteoporosis prophylaxis: 
 35 mg once/wk
    Paget’s disease: 40 mg/day × 6 mo
Risedronate5 Oral Yes 1,000  Osteoporosis treatment and 
 prophylaxis: 35 mg once/wk
    Paget’s disease: 30 mg/day × 2 mo
Ibandronate6,7 Oral or Yes 1,000 Osteoporosis treatment: 150 mg 
  intravenous     orally once/mo or intravenous 
3 mg intravenously every 3 mo
Pamidronate8 Intravenous Yes 1,000–5,000  Hypercalcemia of malignancy: 
 60–90 mg × 1 dose
    Paget’s disease: 30 mg/day × 3 days
     Osteolytic bone metastases: 
 90 mg every 3–4 wks
Zoledronic Intravenous Yes 10,000 Hypercalcemia of malignancy: 
 acid9     4 mg × 1 dose
     Multiple myeloma/bone 
 metastases: 4 mg every 3–4 wks
    Paget’s disease: 5 mg × 1 dose
     Osteoporosis treatment: 
 5 mg once/yr
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shown that the intracortical remodeling rates of 
the jaws are 10–20 times higher than that of the 
iliac crest.66,67 This hypothesis suggests bisphos-
phonate activity may be excessive in the meta-
bolically active jaws leading to bone necrosis 
which quickly becomes exposed bone when the 
thin overlying mucosa breaks down due to minor 
trauma or dental extractions.
Suppression of bone vasculature
Before the emergence of BRONJ, much of what 
was known concerning osteonecrosis centered 
on the two following conditions that manifest as 
a result of disruption of the vasculature. They 
are avascular necrosis of the hip and osteoradi-
onecrosis. Avascular necrosis of the hip occurs 
as a result of disruption of the vasculature.68 
Similarly, osteoradionecrosis, most prominently 
of the jaw, occurs after radiation-induced dis-
ruption of the vasculature.69–71 The existence of 
these conditions, and the clear role of disrupted 
vasculature in their pathophysiology, has led to 
the hypothesis that the vasculature plays a simi-
lar role in the pathophysiology of BRONJ. 
Numerous studies have documented antiang-
iogenic effects of bisphosphonates in vitro.72,73 
However, there have been no studies assessing 
the vascular pattern in BRONJ.
Infection as a contributory factor
It is believed that infection could contribute 
to BRONJ by enhancing osteoclast-independent 
bone resorption. Typically, the exposed bone is sec-
ondarily infected by Actinomyces species and other 
microflora in the oral cavity. BRONJ tissue con-
sistently shows a prevalence of scalloped bone 
surface,69,74,75 a seemingly paradoxical feature, 
given the suppressive effect of bisphosphonates on 
bone resorption. Bacteria and associated fibroblast-
like cells have the capacity to directly resorb bone 
independent of osteoclasts by liberating various 
acids and proteases.76–78 Because osteoclasts 
signal osteoblasts during normal bone remode-
ling,79,80 resorption that occurs independent of 
osteoclasts would likely lack osteoblast-mediated 
bone formation. Such resorption could factor into 
the pathogenesis of BRONJ.
Pathophysiological cofactors
Various cofactors are associated with BRONJ 
such as comorbidities (e.g. diabetes81), lifestyle 
J.B. Lai and C.Y. Poon
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factors (e.g. smoking and obesity82), interventions 
(e.g. dental extraction83), and concurrent medi-
cations (e.g. corticosteroids) have all been associ-
ated with BRONJ. These cofactors individually do 
not cause bone necrosis of the jaws but in the 
presence of bisphosphonates play a significant 
role in the pathophysiology of BRONJ.
Incidence of BRONJ
The incidence of BRONJ with intravenous bi-
sphosphonate ranges from 0.8% to 12%.84–92 
Oral bisphosphonate is associated with lower 
incidence of BRONJ ranging from 0.01% to 
0.04%.83 This increases to 0.09%–0.34% following 
extractions.
Radiologic Finding of BRONJ
The radiologic findings of BRONJ are not specific 
and mimic other conditions such as osteomyelitis, 
osteoradionecrosis, cancer metastasis and Paget’s 
disease. Periapical radiograph and orthopanto-
gram findings include thickening of the lamina 
dura, osteolysis, diffuse sclerosis, narrowing of 
the mandibular canal and poor healing or non-
healing of extraction sites.93–95
Definition and Staging of BRONJ
There are various names to this condition. The 
American association of oral and maxillofacial 
surgeons refer this type of osteonecrosis as “bi-
sphosphonate related osteonecrosis of the jaws”96 
and the Academy of Oral Medicine refers this as 
“bisphosphonate-associated osteonecrosis of the 
jaws”.97 Marx prefers to call this condition as 
“bisphosphonate-induced osteonecrosis of the 
jaws”.98
In this article, we will use the definition pro-
posed by the American Association of Oral and 
Maxillofacial surgeons. BRONJ96 is defined as the 
exposed necrotic bone in the maxillofacial region 
that has persisted for more than eight weeks in 
patients with current or previous treatment with 
a bisphosphonate and with no history of radia-
tion therapy to the jaws. It is a serious and de-
bilitating condition affecting the jaws.
There are four stages of BRONJ, which are as 
follows:
Stage 0  defines signs and symptoms short of ex-
posed necrotic bone in patients that 
might indicate a histological necrosis or 
a prenecrotic state.
Stage 1  defines exposed/necrotic bone in pa-
tients who are asymptomatic and have 
no evidence of infection.
Stage 2  defines exposed/necrotic bone in pa-
tients with pain and clinical evidence of 
infection.
Stage 3  defines exposed/necrotic bone in pa-
tients with pain, infection and one or 
more of the following: pathologic frac-
ture, extra-oral fistula, or osteolysis ex-
tending to the inferior border.
Strategy for Management of Patients on 
Bisphosphonates
Identification of patients at risk of BRONJ
It appears that certain patients are more at risk 
of BRONJ development. Low risk patients can 
be treated in general dental practice settings 
while high risk patients may be referred to an 
oral and maxillofacial surgeon or dental spe-
cialist who has experience in managing such 
patients.
High-risk patients include:
• Cancer patients on intravenous bisphos-
phonate
• Patients on bisphosphonate therapy with ex-
posure to chemotherapeutic agents (i.e. cy-
clophosphamide, erythropoietin, thalidomide 
and steroids)
• Patients on oral bisphosphonate for more than 
3 years
• Patients on bisphosphonate and smoking
• Patients on bisphosphonate and other systemic 
medical conditions (i.e. cancer, diabetes, obes-
ity, atherosclerotic heart disease)
Prevention of BRONJ
Prior to bisphosphonate therapy
A preventive regime should be instituted for 
patients who are about to start intravenous 
bisphosphonates for oncologic reasons. The den-
tition is assessed for carious lesions, defective 
restorations, vitality and periapical lesions. The 
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periodontium (pocketing, furcation involvement, 
bleeding on probing, suppuration, mobility) is also 
examined. The patient’s oral hygiene (plaque, cal-
culus accumulation) is recorded. Oral mucosa 
and alveolar processes are checked for infection, 
ulcerations, hyperplasia, bony spicules and exos-
toses. If patients are edentulous or partially eden-
tulous with removable prostheses, the prostheses 
are checked for fit, retention, stability and hy-
giene. Ill-fitting dentures can cause trauma and 
ulcerations to the oral mucosa and initiate BRONJ. 
Baseline dental radiographs in forms of orthopan-
tograms, bitewings, selective periapical radio-
graphs are required for the detection of occult 
caries and any other pathology, such as cysts, 
buried teeth or roots.
Dental clearance involves the treatment of ac-
tive oral infections, elimination of sites at high risk 
for infection (e.g. removal of partially impacted 
wisdom teeth, unsalvageable teeth, non-restorable 
teeth, teeth with substantial periodontal bone 
loss). Removal of tori and bony exotosis are indi-
cated especially when patients are wearing or 
will be wearing removable prostheses as these 
are sites at risk of bone exposure and initiation 
of BRONJ. Ill-fitting dentures are adjusted and 
fabrication of new dentures may be indicated 
if existing dentures are beyond salvage. It is im-
portant that the new dentures do not cause 
mucosal ulcerations.
All invasive dental procedures should be com-
pleted prior to the start of intravenous bisphos-
phonate. Bisphosphonate therapy should be 
delayed, if systemic condition permits, until the 
extraction site has epithelialized (14–21 days) or 
until there is adequate osseous healing. After the 
initial dental clearance, it is important to provide 
routine dental care afterwards. It is advisable to 
perform oral examination and dental cleaning six 
monthly. Constant surveillance of the oral cavity 
is important to detect any bone exposure so that it 
can be treated early. Oral hygiene in forms of 
tooth brushing, flossing and rinsing with fluoride-
containing mouth rinses, are reinforced. Diet 
counseling in patient with high caries risk, pa-
tient education and motivation are important to 
prevent future caries and periodontal diseases 
development and progression in the remaining 
dentition. All these non-invasive dental proce-
dures can be carried out in general dental prac-
tice setting.
Currently on bisphosphonate therapy
For patients who are already on intravenous bi-
sphosphonates, maintenance and conservative 
dental care are performed as far as possible. 
Conservative measures remain the treatment of 
choice in order to avoid dentoalveolar surgery, 
periodontal surgery and extractions if possible 
to reduce the risk of BRONJ development. Non-
restorable teeth can be treated by decoronation 
and endodontic treatment.
Patients who are receiving oral bisphospho-
nate therapy, routine dental care is encouraged. 
Elective dentoalveolar surgery and extractions are 
not contraindicated, provided the necessary pre-
cautions are taken. For patients on oral bisphos-
phonate therapy for more than 3 years with or 
without concomitant steroid medication, discon-
tinuation of oral bisphosphonate 3 months prior 
to oral surgery should be considered in consulta-
tion with the prescribing physician if the systemic 
condition permits and resumed after osseous 
healing has occurred. Patients with concomitant 
steroid medication are known to be at a slightly 
higher risk of BRONJ and should be informed 
accordingly.
For patients on oral bisphosphonate therapy 
less than 3 years without concomitant steroid 
medication and have no clinical risk factors, den-
toalveolar surgery and extractions can proceed 
without any alterations. For patients on oral bi-
sphosphonate therapy less than 3 years with 
concomitant steroid medication, a 3-month drug 
holiday should be considered, in consultation 
with the prescribing physician.
Biochemical test to assess risk for BRONJ in 
patient on bisphosphonate
Biochemical bone turnover markers are released 
during bone remodeling and can provide a mea-
sure of the rate of bone metabolism. One of these 
bone turnover markers is serum C-terminal tel-
opeptide (CTX). Serum CTX measures the serum 
level of the C-terminal telopeptide-related frag-
ment from a cross-linking chain in type I colla-
gen, which is cleaved by the osteoclast in bone 
resorption. CTX is a measure of the bone resorp-
tion activity and is used as a predictor of bone 
mineral density (BMD) response to bisphospho-
nate therapy.99
Marx and Ranjit100,101 reported the use of CTX 
in predicting the risk of BRONJ related to oral 
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bisphosphonate use. Marx studied a series of 
30 patients who were on oral bisphosphonate 
therapy and correlated them with their serum 
CTX. He concluded that patients with serum CTX 
less than 100 pg/mL representing high risk of 
BRONJ, values between 100 and 150 pg/mL rep-
resenting moderate risk and values above 150 pg/
mL representing minimal risk. Further validation 
studies are required. As its reliability remains con-
troversial the American Association of Oral and 
Maxillofacial Surgeons position paper did not 
include the use of CTX on the management of 
bisphosphonate-related osteonecrosis of the jaws.
Management of BRONJ
The treatment goals of established BRONJ are to 
eliminate pain, control infection of the soft and 
hard tissues and minimise the progression or oc-
currence of bone necrosis.
Patient with BRONJ stage 0
The management of stage 0 patients is es-
sentially preventive and avoids invasive oral sur-
gical procedures and dental extractions as far as 
possible.
Patient with BRONJ stage 1
The management of stage 1 patients is mainly 
conservative. It includes oral antibacterial mouth 
rinse, adjustment of dentures to minimise soft 
tissue trauma or irritation, patient education, reg-
ular quarterly follow-up. Long-term discontinua-
tion of bisphosphonate should be considered 
if the patient’s systemic condition permits after 
discussing with prescribing physician.
Patient with BRONJ stage 2
The treatment of stage 2 patients includes the 
use of oral antibacterial mouth rinse, analgesia 
for pain control, superficial debridement and re-
moval of loose sequestrum to relieve soft tissue 
irritation with minimal disruption to adjacent soft 
tissue and underlying bone and antibiotic therapy 
for the superinfection. Cultures, including those for 
aerobic and anaerobic bacteria may be collected 
to determine the appropriate antimicrobial inter-
vention. The possibility of long-term discontinu-
ation of bisphosphonate if systemic condition 
permits should be considered after consulting 
with the prescribing physician. The infection is 
usually treated with empirical broad-spectrum 
oral antibiotics such as penicillin V or amoxicillin. 
If patient is allergic to penicillin, clindamycin can 
be used. Other alternative antibiotics include ery-
thromycin ethylsuccinate, doxycycline together 
with metronidazole, levofloxacin and moxiflox-
acin. Once the culture and sensitivity result is 
available, specific antibiotic therapy should be 
instituted.
Patient with BRONJ stage 3
The management of stage 3 patients is essentially 
similar to that of stage 2 patients. More aggres-
sive surgical debridement or resection to achieve 
longer term palliation of infection and pain may 
be necessary. The effectiveness of hyperbaric 
oxygen therapy is still undetermined.
Examples of Local Cases With BRONJ
Case 1
A 60 year-old Chinese female presented with non-
healing socket over upper right canine region of 
4-month duration. She also complained of recur-
rent epitaxis from the right nose. ENT examina-
tion was unremarkable. She was diagnosed with 
osteoporosis and has been on oral alendronate 
(Fosamax) for the past 4 years.
Clinical examination revealed sinus tract over 
upper right canine region (Figure 1). Anterior max-
illary occlusal showed radiolucent defect over 
the above region (Figure 2).
Fosamax was discontinued. She underwent sur-
gical debridement and exploration under local 
anaesthesia. Figure 3 showed sequestrum with 
defect from alveolar ridge to right piriform rim. 
Tissues were submitted for histology and results 
showed sequestrum which is consistent with 
BRONJ given the medical history. She was reviewed 
and the region healed uneventfully 1 year later.
Case 2
A 59 years-old Malay female with medical history 
of breast cancer with bone metastasis presented 
with stage II BRONJ over left lower posterior 
ridge. She developed 3 mm of exposed bone af-
ter eight doses of IV bisphosphonate zoledronic 
acid (Zometa) and oral chemotherapy. IV 
bisphospho nate was discontinued and BRONJ 
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Case 3
A 45-year-old Chinese female with medical history 
of breast cancer with bone metastasis presented 
with exposed bone and multiple sinus tracts over 
the right maxilla. She was treated with IV bisphos-
phonate zoledronic acid (Zometa). She was diag-
nosed with stage III BRONJ over the right maxilla 
(Figure 6) and was not responsive to conservative 
treatment. Right maxillectomy was performed to 
alleviate pain for the patient. Figure 7 showed the 
resected right maxillary bone sequestrum.
Conclusion
Patients on bisphosphonate therapy may develop 
BRONJ which is a rare but debilitating condition. 
Figure 1. Sinus tract over upper right canine region.
Figure 2. X-ray showing lytic lesion secondary to 
BRONJ.
Figure 3. Sequestrum and granulation tissue.
was resolved 3 months after cessation of the 
medication. Figure 4 showed radiolucent and 
lytic appearance and Figure 5 showed the healed 
region with normal cortical outline.
Figure 4. Lytic region with BRONJ over posterior 
alveolar crest.
Figure 5. Resolution of the lesion after 3 months bi-
sphosphonate cessation.
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BRONJ is difficult to treat and patients may even 
require jaw resection to palliate the infection 
and pain. Therefore, it is important for the dental 
community to be familiar with the management 
of these patients in collaboration with our medical 
colleagues.
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